维生素D补充与安慰剂在首发精神病患者中的比较——神经保护设计(DFEND):一项随机双盲安慰剂对照平行组试验的方案
DFEND研究是一项多中心随机双盲安慰剂对照平行组试验,纳入符合ICD-10功能性精神病诊断的早期精神病患者,按1:1随机接受每月120000 IU维生素D(胆钙化醇)或匹配安慰剂治疗6个月。主要结局为所有患者6个月随访时阳性与阴性症状量表(PANSS)总分,次要结局包括情绪、一般功能、心血管风险及维生素D水平。该研究旨在探讨大剂量维生素D补充对早期精神病结局的影响,假设补充维生素D与更好的心理健康结局相关。
要点
- 早期精神病患者随机接受每月120000 IU维生素D或安慰剂治疗6个月。
- 主要结局为6个月时PANSS总分,次要结局包括情绪、功能及心血管风险指标。
- 对基线维生素D不足者额外分析3个月和6个月PANSS总分。
核心结论
- DFEND研究旨在检验早期精神病中维生素D补充是否与更好的心理健康结局相关。
- 研究结果可能有助于解决关于精神病患者常规补充维生素D的获益与成本效益的临床均衡问题。
研究设计与样本
- 多中心、双盲、安慰剂对照、平行组随机试验。
- 纳入符合ICD-10功能性精神病诊断的早期精神病患者,按1:1随机分配。
- 干预组每月接受120000 IU维生素D(胆钙化醇),对照组接受匹配安慰剂,疗程6个月。
- 主要结局为所有患者6个月随访时PANSS总分。
关键数值与推荐
- 干预剂量为每月120000 IU维生素D(胆钙化醇),疗程6个月。
- 主要结局为6个月随访时PANSS总分。
- 次要结局包括加尔加里抑郁量表、全局功能评估、体重指数、腰围、C反应蛋白、胆固醇、HbA1c及维生素D水平。
- 对基线维生素D水平不足者分析3个月和6个月PANSS总分。
临床怎么用
- 该研究为早期精神病患者补充维生素D的临床决策提供证据,但方案阶段尚不能给出实践推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People experiencing their first episode of psychosis are often deficient in vitamin D. Observational studies have reported an association between low vitamin D concentrations and poorer subsequent health outcomes in psychosis. A vitamin D deficiency in neonates and children has been linked to a later increased risk of schizophrenia and psychotic-like experiences. This trial aims to examine the effect of high-dose vitamin D supplementation on outcomes in early psychosis. We hypothesise that vitamin D supplementation will be associated with better mental health outcomes. METHODS/DESIGN: The DFEND study is a multicentre double-blind placebo-controlled parallel-group trial of vitamin D supplementation in people with early psychosis. Patients with an ICD-10 diagnosis of functional psychosis will be randomised in a 1:1 ratio to receive either 120,000 IU/month of vitamin D (cholecalciferol) or a matched placebo for 6 months. The primary outcome is the total Positive and Negative Syndrome Scale (PANSS) score at the 6-month follow-up for all patients. Secondary outcomes include assessment of mood (Calgary Depression Scale), general function (Global Assessment of Functioning), cardiovascular risk (body mass index, waist circumference, C-reactive protein, cholesterol and HbA1c) and vitamin D levels at the 6-month follow-up. Additionally, 3- and 6-month total PANSS scores will be analysed for those with inadequate vitamin D levels at the baseline. DISCUSSION: The DFEND study is the first trial to examine whether vitamin D supplementation in early psychosis is associated with better mental health outcomes. The findings of this study may help to resolve the clinical equipoise regarding the benefits and cost-effectiveness of routine vitamin D supplementation in people with psychosis. TRIAL REGISTRATION: ISRCTN, ISRCTN12424842. Registered on 25 February 2015.
引用
- Gaughran F, Stringer D, Berk M, et al. Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial. Trials. 2020. PMID: 31907006. doi:10.1186/s13063-019-3758-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。